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Abstract 
 In blood malignancies, the balance of hematopoietic stem cell (HSC) self-renewal 
and differentiation is disturbed such that HSCs produce abnormal cells with an increased 
capacity to proliferate; however, the exact causes of this imbalance are not known. 
SpeedyA1 (Spy1) is a positive cell cycle regulator known to enhance cellular proliferation 
by direct binding and activation of Cyclin-dependent kinase (Cdk) Cdk2 and by 
promoting degradation of the Cdk inhibitor (CKI) p27
Kip1
. I demonstrate that Spy1 
expression levels are elevated in early stem and progenitor cells during hematopoiesis, 
but that Spy1 may also be implicated in later stages of myeloid differentiation. Spy1 
protein was elevated in human bone marrow tumour samples and Spy1 knock-down in 
HL-60 cells led to decreased cell growth as well as expression of leukemic stem cell 
(LSC) markers. Together, these findings demonstrate a potential role for Spy1 in 
regulating HSC fate and in the development of blood malignancies. 
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INTRODUCTION 
 
In Canada, there are approximately 90,000 people diagnosed with, or in remission 
from, a variety of blood malignancies including leukemia and lymphoma
1
.
 
Leukemia and 
lymphoma are the most common cancers diagnosed in children and youth under the age 
of twenty; these groups of cancers account for approximately one third and one fifth of 
childhood cancers, respectively
1-3
.
 
While advances in treatment have drastically improved 
survival rates for some types of blood cancers
4-11
, there are still many for which a cure 
has yet to be discovered
4,12-13
.
 
Complicating the discovery of new treatments is the 
enormous diversity among different types of blood cancers, each presenting with a 
different genetic background not yet fully elucidated. Therefore, it is of utmost 
importance to resolve the causes of blood cancers on a cellular and molecular level so that 
better treatments can be implemented. 
 
I. Hematopoiesis: Blood Cell Development 
 
The production and development of blood cells is a process known as 
hematopoiesis. This process is arranged in a hierarchy such that all blood cells are derived 
from a primitive hematopoietic stem cell (HSC) that is responsible for maintaining 
homeostasis of the blood system (Figure 1)
14-15
. HSCs, like other stem cells, have the 
unique ability to undergo asymmetric cellular division. Thus, they not only give rise to 
more differentiated blood cells to produce all the many types of blood cells found in the 
body, but they also generate more stem cells through self-renewal to maintain the pool of 
adult stem cells. 
Although HSCs were discovered over 50 years ago by McCulloch and Till
16-18 
and 
first isolated over 20 years ago
19
, it was not until recently that HSCs were discovered to  
1
  
 
 
 
 
 
 
 
 
 
Figure 1. Hematopoietic Cell Development. Primitive HSCs give rise to all blood 
cells of the body through a series of steps in which cells get progressively more 
committed. LT-HSC, long-term repopulating HSC; ST-HSC, short-term repopulating 
HSC; MPP, multipotent progenitor cell; CMP, common myeloid progenitor; CLP, 
common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, 
granulocyte-macrophage progenitor. (from Larsson, J. And Karlsson, S. Oncogene 
2005)
14
 
2
be a heterogeneous population of stem cells with differential reconstitution ability
20-22,23
. 
In fact, different kinds of HSCs have now been characterized and isolated within the 
human hematopoietic system
22-29
. The long-term repopulating HSC (LT-HSC) is thought 
to be responsible for life-long maintenance of the adult stem cell pool
22
. LT-HSCs are 
relatively rare, representing <0.01% of cells found in the adult bone marrow
30-31
.
 
These 
stem cells, when transplanted into irradiated mice, have been shown to be capable of 
retaining engraftment potential indefinitely
22
.
 
LT-HSCs are relatively inactive, dividing 
infrequently to produce more rapidly proliferating short-term repopulating HSCs (ST-
HSCs) which give rise to multipotent progenitors (MPPs) with a decreased ability for 
self-renewal
22,32
.
 
MPPs can differentiate into the common lymphoid progenitor (CLP) 
and/or the common myeloid progenitor (CMP)
 
and at this point in hematopoiesis, blood 
cell development is restricted to the CLP or CMP lineage
14-15
.  
Through a series of differentiation steps, CLPs will give rise to white blood cells 
important for the functioning of the lymphatic system such as B-Lymphocytes, T-
Lymphocytes, and Natural Killer cells
14-15
. CMPs give rise to erythrocytes, 
megakaryocytes, granulocytes, and monocytes
14-15
.
 
Erythrocytes (red blood cells) contain 
hemoglobin and transport oxygen throughout the circulatory system
 
and megakaryocytes 
produce platelets which are important in the formation of blood clots
33-34
. Monocytes are 
white blood cells that produce macrophages which are important in destroying bacteria
33-
34
. Granulocytes are white blood cells important to the functioning of the human immune 
system and include neutrophils, eosinophils, and basophils
33-34
. 
The fate of HSCs is highly dependent on different growth factors present in the 
microenvironment. While the roles of several growth factors and cytokines in 
hematopoietic lineage decisions have been resolved, it is important to note that 
3
interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) are important in 
specifying a myeloid fate
30,35
, whereas a lymphoid fate is largely controlled by the 
presence of interleukin-7 (IL-7)
30
. 
 
II. Mammalian Hematopoietic Development 
 
The hematopoietic system is one of the first mammalian tissue systems to form in 
the developing embryo
36-37
. Primitive erythrocytes can be found in the blood islands of 
the extra-embryonic yolk sac early on in embryonic development
36-37
. However, 
definitive HSCs, capable of hematopoietic reconstitution upon engraftment in an adult 
irradiated mouse, are first observed in the aorta-gonad-mesonephros (AGM)
36-38
. In 
humans HSCs in the AGM are seen as early as embryonic day 27, indicating that the 
AGM is the first site of hematopoiesis in the developing embryo
37
. 
There are several developing organs involved in fetal hematopoiesis, including the 
liver, spleen, thymus, and bone marrow, that can contribute to fetal blood cell production 
after first being colonized by migrating blood cells
34,36-37,39-40
. Beginning as early as 
embryonic week 5 in humans the liver plays a distinctive role in fetal hematopoiesis as it 
supports proliferation and differentiation of the colonizing progenitor cells
37
. 
Nonetheless, it is not until later in embryonic development that the human fetal liver 
produces definitive HSCs that express the stem cell marker CD34 and have the capacity 
to undergo hematopoiesis in vitro
37,39
. At this point, the liver is the primary organ 
responsible for human fetal hematopoiesis
37
. 
The bone marrow is the last tissue important for hematopoietic development that 
is established in utero. The bone marrow microenvironment begins to form around 10 
weeks during human embryonic development and primitive myeloid and erythroid cells 
4
can be found in the developing marrow as early as week 11
37
.
 
However, HSCs capable of 
hematopoietic reconstitution are not observed in the marrow until right before birth
37
.
 
At 
this time, blood development is diminished in the yolk sac and occurs only to a limited 
extent in the liver
37
.
 
This sequence of events has been shown to be very similar to that of 
hematopoietic development in mice
36
. 
The bone marrow will sustain hematopoiesis on a long-term basis for the 
remainder of the mammalian lifespan. However, other organs also serve important 
hematopoietic functions in the adult mammal. First, the spleen aids in red blood cell 
turnover as it is responsible for the destruction of damaged red blood cells; it also 
contributes to white blood cell synthesis
40
. In addition, the thymus plays a role in adult 
lymphocyte maturation
40
.
 
Moreover, the adult liver is also involved in the turnover of red 
blood cells
40 
and has been found to contain small populations of adult HSCs
41
.
 
HSCs can 
also be found in very small numbers in the circulating peripheral blood. An understanding 
of the role each secondary hematopoietic tissue plays in hematopoiesis is important as 
both fetal and adult tissues were examined in this work.  
 
III. HSC Quiescence 
 
The majority of adult HSCs, like other adult stem cells, remain in a relatively 
inactive state with low turnover referred to as quiescence
32,42-43
.
 
HSC quiescence is 
largely controlled by cell cycle inhibitors at G1 phase of the cell cycle including p21, p27, 
and p57 as well as by the tumour suppressor protein p53
44-47
.
 
The infrequent division of 
HSCs acts as a protective mechanism to limit DNA damage and to prevent premature 
proliferative exhaustion of the stem cell pool
32,42-43
. However, as previously mentioned, 
HSCs do enter the cell cycle occasionally to give rise to ST-HSCs that will support the 
5
continuous production of many types of blood cells
32,42-43
. Furthermore, under times of 
physiological stress on the hematopoietic system such as injury or severe blood loss, adult 
HSCs are capable of exiting quiescence and rapidly proliferating to repopulate the 
hematopoietic system
42
. Thus, HSCs are relatively quiescent under homeostatic 
conditions, but retain the ability to rapidly self-renew when necessary. 
 
IV. Hematopoietic Malignancies: Subtypes 
 
Leukemia is primarily a disease of the hematopoietic system affecting organs such 
as the bone marrow and circulating blood. There are many different subtypes of leukemia 
that are classified based on the type of blood cell that is affected. Lymphoblastic or 
lymphocytic leukemia initiates in a marrow cell that is a precursor of a lymphocyte
48
. 
Myelogenous or myelocytic leukemia initiates in a marrow cell that is destined to become 
a red blood cell, platelet, or a type of white blood cell other than a lymphocyte
48
. 
Leukemia can be further classified into several subtypes based on how quickly the disease 
develops and on the maturation stage of the cells as determined by staining and pathology 
analysis
48
.
 
Chronic leukemia takes months, sometimes even years, to develop and is most 
common in adults
3,48
. On the other hand, acute leukemia, the most common form of 
leukemia in children
3
, has a rapid onset and can progress much more quickly
48
.  
Similar to lymphocytic leukemia, lymphomas involve abnormally proliferating 
lymphocytes. Unlike leukemia however, lymphoma results in the formation of masses of 
tumourigenic cells in the lymph nodes. The cancer can also spread to the liver, spleen, 
and other parts of the lymphatic and immune system; metastases to the lungs, bone, and 
central nervous system are also known to occur
3
. 
6
Finally, a blood disorder known as myeloma also exists. Multiple myeloma is the 
second most common hematological malignancy and accounts for approximately 1% of 
all cancers
49
.
 
This disease primarily develops in B lymphocytes as they mature in the 
marrow to become plasma cells
49
. Cancerous plasma cells grow very rapidly and, in 
doing so, they prevent normal production of healthy blood cells and platelets; the end 
result is the formation of tumours in the marrow of the bones affected. Myeloma cells can 
invade and weaken the bones causing what are known as osteolytic lesions or bone 
lesions
49
.
 
A plasmacytoma refers to a patient with a bone lesion or tumour in only one 
site, whereas, multiple myeloma refers to a patient with tumours in the marrow of 
multiple bones
49
. 
 
V. Blood Malignancies: Involvement of Cell Cycle Proteins 
Although there are several different types of blood cancer, each affecting different 
kinds of blood cells at different stages of hematopoietic development, the common 
hallmark of blood cancers is an abnormal proliferation of specific kinds of blood cells. 
While the molecular mechanisms driving this abnormal proliferation have not been fully 
elucidated, several cell cycle proteins have been found to be implicated in different blood 
malignancies. 
The mammalian cell cycle is largely regulated by a family of protein kinases 
called Cyclin dependent kinases (Cdks) that, when bound to Cyclin proteins, can promote 
progression through the cell cycle. In addition to cyclin binding, Cdks are activated post-
translationally via phosphorylation by Cdk activating kinase (CAK) and removal of 
inhibitory phosphates by the Cdc25 phosphatases. Cdks are also negatively regulated by 
Cdk inhibitors (CKIs), such as the Cip/Kip family of inhibitors which bind to Cdk-Cyclin 
7
complexes and interfere with the proper folding of the catalytic cleft, thereby, rendering 
the complex inactive. The Cip/Kip family includes p27
Kip1
, p21
Cip1
 and p57
Kip2
.  
Several blood malignancies have been found to display elevated Cdk levels and 
low levels of CKIs have been associated with poor prognosis in patients
50-52
.
 
For example, 
leukemia patients with low levels of p27 have presented with a worse prognosis
51
 and 
aberrant regulation of p21 has also been demonstrated in many human leukemias
44
. 
Furthermore, an increase in Cdk2 activity has been observed in both lymphoid and 
myeloid derived leukemias as well as in some lymphomas
50,52
. This increase has partly 
been attributed to the abnormal localization of p27 in the cytoplasm where it cannot 
inhibit activity of Cdk2
52
. 
 
 
VI. Cancer Stem Cell Hypothesis & Leukemic Stem Cells 
 
A population of cells known to drive tumour growth has been shown to exist in 
many cancers
15,53-57
. These cells, termed cancer stem cells (CSCs) possess similar 
characteristics of normal stem cells in that they can propagate themselves and also 
differentiate; thereby, they can not only sustain growth of the cancer, but can also give 
rise to the many differentiated cell types found within a heterogeneous tumour
15,58
. 
The existence of CSCs in blood malignancies was originally hypothesized based 
on the observation that only a very small percentage of human leukemia cells had 
clonogenic properties
59-60
. However, the first conclusive evidence for the existence of 
CSCs in leukemia came from the identification of a rare population of human acute 
myeloid leukemia (AML) cells that could generate leukemias representative to the human 
disease in xenograft transplants
53,61-62
.
 
These CSCs, called leukemic stem cells (LSCs), 
8
were later shown to continuously generate leukemias in murine serial transplantation 
experiments, indicating that they possessed an indefinite potential to self-renew
58,63
. 
Although the discovery of LSCs in AML has prompted much research in the area, 
the origin of LSCs has not yet been completely resolved. LSCs may result from the 
transformation of normal HSCs or they may arise from mutations or epigenetic changes 
in more committed progenitor cells allowing for enhanced self-renewal
64-65
. Interestingly, 
there has been evidence to support that AML is organized in a hierarchy with distinct 
classes of LSCs with differential long term repopulating (self-renewal) potential similar 
to that of HSCs
53,58
.
 
Resolving the ambiguity surrounding the origin of the LSC will aid in 
the determination of specific molecular markers that are differentially expressed in 
normal and leukemic stem cells. This is a necessary step in targeting LSCs to eradicate 
this population therapeutically. To date, a few cell surface markers have been found to be 
commonly deregulated in leukemias and researchers are beginning to exploit these for 
drug design and clinical trials
66-70
. In AML the markers CLL-1 and CD33 have been 
identified as potential therapeutic targets for the eradication of LSC populations
67-70
. 
Although possessing the ability to rapidly self-renew, many LSCs have been 
shown to be quiescent, similar to LT-HSCs
58,64,71-72
. This low cycling state provides the 
same protective advantages to LSCs as it does to normal HSCs, limiting DNA damage 
and preventing exhaustion of the LSC population
72
.
 
LSCs are also known to contain an 
abundance of ATP-Binding Cassette Transporters (ABC Transporters)
73
. ABC-
transporters are proteins known to efficiently pump chemotherapeutics out of the cell, 
contributing to drug resistance. The presence of ABC-transporters and the relatively low 
cycling rate of LSCs makes them highly resistant to conventional therapies, especially 
those involving chemotherapeutic drugs
55,58,64,71-73
. Thus, LSCs often persist in the patient 
9
post-treatment and can initiate disease relapse (Figure 2)
55,64,71,73
.
 
It is extremely 
important to uncover novel ways to target the LSC population in different blood 
malignancies to successfully induce disease remission. This requires resolving the 
origin(s) and mechanisms behind the development of LSCs. 
 
 
VII. Spy1 
 
SpeedyA1 (Spy1) was initially identified by two independent groups. Ferby and 
colleagues demonstrated that a novel protein, p33-RINGO (Rapid Inducer of G2-M 
Progression in Oocytes) was sufficient to initiate oocyte maturation in Xenopus and that 
depletion of this protein inhibited progesterone-induced oocyte maturation
74
. Similarly, 
Lenormand and colleagues also discovered a novel protein, Spy1, that could induce 
Xenopus oocyte maturation and that this was dependent on activation of the MAPK 
pathway
75
. 
To date, Spy1 is known to be expressed in a variety of human tissues and cell 
lines
76
; of particular interest to this study are the thymus and the liver. Spy1 was also 
found to be a nuclear protein and to be expressed in a cell cycle dependent manner, 
peaking in G1/S phase
76
. Although Spy1 has no sequence homology to the Cyclin 
proteins, it has been found to be capable of binding and activating both the G2/M Cdk, 
Cdk1, and the G1/S Cdk, Cdk2
74-77
. Interestingly, Spy1 can activate Cdk1 and Cdk2 in 
the absence of phosphorylation of the respective Cdks on Thr-161 and Thr-160; a 
modification normally required for Cdk kinase activity
77
.
 
In addition, Spy1-Cdk2 
complexes have been found to have broader substrate specificity than other Cyclin-Cdk2 
complexes, suggesting that Spy1 may alter the substrate specificity of Cdk2
78
. Taken 
together, the novel activation and altered substrate specificity of Cdk2 by Spy1 may result  
10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. LSC Hypothesis. (A) The LSC hypothesis predicts that the leukemic blast cell 
population is maintained by a small subset of tumourigenic cells with stem cell properties. 
LSCs can self-renew and differentiate to maintain the heterogeneous tumour. (B) Current 
treatments do not target LSCs so they persist and can initiate relapse. Novel treatment 
designs that target LSCs may help eliminate the entire malignancy. (from Guzman, M.L. 
and Jordan,C.T. Cancer Control 2004)
55
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in aberrant proliferation at times when it may be inappropriate; this represents one way in 
which Spy1 could contribute to tumourigenesis. 
Additionally, Spy1 is capable of overriding normal cellular responses to stress 
such as apoptosis, senescence, and DNA damage response pathways
79
. It is known that 
endogenous Spy1 levels increase in cells following treatment with DNA damaging agents 
and that the overexpression of Spy1 enhances cell survival in the presence of such agents 
by preventing apoptosis and interfering with repair pathways
79-81
. Specifically, the 
overexpression of Spy1 prevents cells from efficiently activating both G1/S and G2/M 
phase checkpoints following exposure to ultraviolet radiation and the activation of DNA 
damage response pathways increases in the absence of Spy1
79,81
. Moreover, Spy1-Cdk 
complexes demonstrate decreased sensitivity to inhibition by the cell cycle inhibitor, 
p21
Cip1
 and Spy1 has been shown to be capable of overriding the p27
Kip1
-mediated 
checkpoint at G1/S phase of the cell cycle
77,82-83
. Collectively, these findings have 
demonstrated that Spy1 can also contribute to tumourigenesis by promoting cell cycle 
progression even in the presence of cellular stressors. 
Recent data from our lab have demonstrated a role for Spy1 in maintaining 
stemness in the breast and the brain
84
. In addition, Spy1 is known to be elevated in many 
human cancers and it has been recently reported as important in human non-hodgkin’s 
lymphomas
85
. Hang and colleagues found that Spy1 protein was highly expressed in a 
variety of different types of human non-hodgkin’s lymphoma samples and that this 
expression was correlated with that of proliferation markers
85
. Importantly, they found 
that patients with high levels of Spy1 protein had a worse prognosis and decreased overall 
survival compared to patients with lower levels of Spy1 protein
85
. 
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The goals of this study were to explore the involvement of Spy1 in normal 
hematopoietic cell development and to determine its role in human blood malignancies. 
Initially, I sought to examine the expression of Spy1 in different hematopoietic tissues 
and to establish a role for Spy1 in hematopoietic fate decisions in vitro. Secondly, I aimed 
to discover whether Spy1 may be implicated in hematopoietic malignancies, particularly 
those known to contain LSC populations. 
 
Objective 1: Determine a role for Spy1 in hematopoietic stem cell fate. EML cells were 
utilized as a model system of hematopoietic development. These are murine bone marrow 
cells representative of MPP populations that are capable of responding to differentiation 
stimuli to generate differentiated blood cells of the erythroid, myeloid, and lymphoid 
lineages
30,86
.
 
Spy1 expression was examined during the myeloid differentiation of EMLs 
in vitro.  
 
Objective 2: Study the role of Spy1 in the development of hematopoietic malignancies. 
HL-60 cells were used as a representative case of acute myeloid leukemia as Spy1 is 
known to be highly expressed in this line. Short hairpin RNA (shRNA)-mediated knock-
down of Spy1 was performed and growth assays were used to study the effects of Spy1 
depletion on leukemic cell growth. Gene expression levels of known LSC markers in 
AML were also studied following shRNA-mediated depletion of Spy1.  Moreover, 
analysis of Spy1 protein levels in human bone marrow tumours was also performed. 
 
Collectively, this study aims to broaden the understanding of novel cell cycle regulators 
during normal hematopoiesis and in various blood malignancies, particularly AML. The 
13
findings of this study have identified Spy1 as important in regulating HSCs and have 
suggested a potential role for Spy1 in LSC populations. Overall, the outcomes of this 
study may have important implications in the treatment of blood malignancies. 
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MATERIALS AND METHODS 
I. Tissue Microarray Analysis 
Paraffin-embedded Tissue Microarray slides (US BioMax) were first baked at 
60˚C to remove paraffin. Immersion in xylene for 10 minutes, followed by subsequent 
immersion in 100% ethanol, 95% ethanol, and 70% ethanol for 5 minutes each was then 
performed to rehydrate the slide. After being washed in 1X PBS for 5 minutes, slides 
were immersed in sodium citrate buffer (pH 6.0) at 95ºC for approximately 15 minutes 
for antigen retrieval. Slides were then stained with different antibodies. Specifically, a 
blocking antibody (normal goat serum; Cayman Chemical 10006577) was applied to the 
slides at room temperature for 20 minutes followed by application of anti-Spy1 antibody 
at a dilution of 1:100 (Novus Biologicals NB100-2521) for 60 minutes also at room 
temperature. Slides were washed twice for 5 minutes in 1X PBS prior to application of a 
fluorescence-conjugated secondary antibody (Alexa488-goat anti-Rabbit IgG; Invitrogen 
A11008) at a dilution of 1:1300 for 20 minutes at room temperature in the dark. Slides 
were again washed in 1X PBS before application of TOTO-3 nuclear stain (1:1300; 
Molecular Probes T-3600) for 20 minutes in the dark. After a final wash in 1X PBS for 5 
minutes, slides were immersed subsequently in 70%, 95%, and 100% ethanol for 5 
minutes each, followed by immersion in xylene for 8 minutes. Slides were mounted to 
coverslips and ScanArray Express software (Perkin Elmer Inc.) was used to detect and 
quantify fluorescence. Data were normalized to the nuclear stain, TOTO-3. To control for 
non-specific signals, slides were compared to previously established slides stained with 
secondary antibody alone. 
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II. Murine Hematopoietic Tissue Extraction 
Balb-C mice were humanely sacrificed at post-natal day 7 and every week 
thereafter for 6 weeks for the extraction of tissues. All dissection tools were sterilized 
prior to use. Incisions were made on the ventral surface of each mouse beginning at the 
posterior end and moving anteriorly up the centre of the mouse to expose the body cavity 
and the internal organs. Samples of the liver, spleen, and thymus were cut, placed in an 
eppendorf tube and flash frozen in liquid nitrogen prior to storage. Peripheral blood was 
extracted using a syringe and needle. Bone marrow samples were obtained by flushing the 
bones of the hind limbs with 1X PBS; bone marrow from both left and right femurs and 
tibias were pooled. Red blood cells were removed by incubation with red blood cell lysis 
buffer (Sigma R7757) for up to 5 minutes on ice followed by centrifugation at 1200 rpm 
and 4ºC for 5 minutes. All samples were flash frozen in liquid nitrogen prior to storage in 
a -80ºC freezer. Three samples of each tissue were taken from one mouse for each time 
point. 
 
III. Protein Extraction 
Murine tissue samples were lysed and homogenized using a Sonic 60 
Dismembrator (Fisher Scientific FM2602) followed by centrifugation for 20 minutes at 
10,000 rpm and 4ºC to remove any fat or undesired tissues. For lysates in which fat was 
still present, a second centrifugation was necessary. Lysis buffer was composed of 0.1% 
Nonidet P-40, 50 mM Tris-HCl pH 7.4, 0.25% Deoxycholate acid, 1 mM EGTA pH 8.0, 
0.2% SDS, and 150 mM NaCl. The following protease inhibitors were added: PMSF (10 
µL/mL); Leupeptin (1 µL/mL); and Aprotinin (0.5 µL/mL). Protein lysates were stored at 
-80ºC.  
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IV.  Immunoblotting 
Protein concentrations of lysates were determined using the Micro-BCA protein 
assay kit (Thermo Scientific). Briefly, protein lysates were mixed with a working reagent 
in a 1:1 ratio and allowed to incubate at 60ºC for 60 minutes prior to analysis of 
absorbance at 562 nm in a spectrophotometer (Biomate 5, Thermo Electron Corporation 
BIO 145108). All protein concentrations were corrected to the reading of lysis buffer. A 
total of 50 to 100 µg of lysate was prepared in 4X sample buffer (10% glycerol, 62.5 mM 
Tris-HCl pH 6.8, 2% SDS, 0.01 mg/mL bromophenol blue, and 2% β-mercaptoethanol), 
boiled for 5 minutes, and run on a 10% SDS gel for 3 hours at 120 volts. Gels were 
transferred onto PVDF membrane (Millipore IPVH00010) for 2 hours at 30 Volts and 
membranes were subsequently blocked in 1% milk for a minimum of 45 minutes. 
Membranes were blotted with either anti-Spy1 antibody (Novus Biologicals NB100-
2521) or anti-Spy1 antibody (AMICUS Biotech) overnight at 4ºC for detection of Spy1 or 
with anti-actin monoclonal antibody (Chemicon Intl. MAB1501R) for 1 hour at room 
temperature for detection of a loading control protein. Secondary antibodies were either 
anti-rabbit IgG (Sigma A0545) or anti-goat (Santa Cruz sc-2020) for Spy1 and anti-
mouse IgG (Sigma A9917) for actin. All secondary antibodies were applied at room 
temperature for 1 hour. Membranes were washed in between primary and secondary 
antibody applications with TBS-Tween. Protein was visualised and densitometry was 
analyzed using FluorChem HD2 imaging software (Alpha Innotech). Only results 
obtained with the Spy1 antibody from Novus Biologicals are shown. 
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V. Cell Culture 
EML cells were purchased from American Type Culture Collection (CRL-11691) 
and cultured in Iscove’s Modified Dulbecco’s Medium (IMDM; ATCC 30-2005) 
supplemented with 20% heat-inactivated fetal bovine serum (hiFBS; Invitrogen 906532), 
1% penicillin/streptomycin solution (P/S; GIBCO 991805), and 50 ng/mL murine stem 
cell factor (SCF; MyBioSource MBS400071). EML cells were maintained at a cell 
density of 2.0 x 10
5 
cells/mL and 2 x 10
6 
cells/mL and passaged every 2 to 3 days. HL-60 
cells were a kind gift of Dr. Michael Boffa (University of Windsor, Biochemistry 
Department) and were cultured in IMDM supplemented with 20% FBS and 1% P/S. All 
cells were maintained in a 37°C humidified incubator set to 5% CO2. 
 
VI. Differentiation of EML Cells 
To induce differentiation of EML cells into myeloid progenitor cells, 1 x 10
5 
cells/mL were seeded in either 12 or 6 well plates. Differentiation media consisted of 
complete growth media (IMDM with 20% hiFBS, 1% P/S, 50 ng/mL SCF) with the 
addition of 10 ng/mL murine interleukin-3 (IL-3; Peprotech 213-13), and 10
-5 
all-trans 
retinoic acid (atRA; Sigma R2625). Control cells were grown in the absence of IL-3 and 
atRA. All plates containing atRA were stored in the dark. Cells were collected by 
centrifugation at 0, 24, 48, and 72 hours after the addition of differentiation media.  
Myeloid progenitor cells generated by 72 hours of growth in media containing IL-
3 and atRA were maintained in IMDM supplemented with 20% hiFBS, 1% P/S, and 10 
ng/mL murine granulocyte macrophage-colony stimulating factor (GM-CSF; Peprotech 
315-03). After 5 to 7 days of incubation with GM-CSF, myeloid progenitor cells were 
selected. To induce terminal differentiation, GM-CSF-dependent myeloid progenitor cells 
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were seeded at a density of 1 x 10
5 
cells/mL in either 12 or 6 well plates in complete 
growth media containing 10 ng/mL murine GM-CSF and 10
-5 
M atRA. Control myeloid 
progenitor cells were grown in the absence of atRA. All plates with media containing 
atRA were stored in the dark. Cells were collected by centrifugation at 0, 24, 48, and 72 
hours after the addition of atRA.  
 
VII. EML Immunomagnetic Cell Sorting 
To obtain a CD34+ population of cells, EML cells were sorted using Dynabeads 
M-450 Epoxy (Invitrogen 140.11) and an EasySep Magnet (Stem Cell Technologies 
18000) according to the manufacturer’s protocol. Briefly, magnetic beads were 
conjugated to anti-CD34 antibody (Santa Cruz IC0115) by incubation for 16 to 24 hours 
on a mutarotator at room temperature (5 µg anti-CD34 per 25 µL of Dynabeads). 25 µL 
of CD34-conjugated magnetic beads and 25 µL buffer (0.1% BSA in 1X PBS) were 
allowed to incubate with 2.5 x 10
6
 cells at 4ºC for 20 minutes with gentle rotation on a 
mutarotator. This ratio was scaled up or down depending on the starting cell number. 
Following this, a magnetic field was applied for 1 minute in the EasySep Magnet causing 
CD34+ cells to be pulled to the inner walls of a test tube so that CD34- cells could easily 
be obtained by removal of the buffer. Several 2 to 3 minute washes with 0.1% BSA buffer 
removed the CD34+ cells. CD34- and CD34+ cells were plated in 6 well tissue culture 
plates for approximately 1 week prior to collection, along with a heterogeneous 
population of EML cells, for further analysis. 
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VIII. HL-60 Lenti-viral Infections 
All HL-60 cell infections were performed in either 96 or 24 well plates. 5.0 x 10
4 
cells/well were seeded for infections in 96 well plates and 1.0 x 10
5
 cells/well were 
seeded for infections in 24 well plates. For all infections, HL-60 cells were seeded in 
serum-free and antibiotic-free IMDM containing 1 µg/mL polybrene (SantaCruz sc-
134220). Cells were allowed to incubate with polybrene-containing media for 
approximately 20 minutes before the addition of virus. Cells were infected with a vector 
carrying shRNA against Spy1 (pLKO-shSpy1) and control cells were infected with 
pLKO-shScrambled (pLKO). Lenti-virus was used at a titre of 10
7
 transducing units 
(TU)/mL and a multiplicity of infection (MOI) of 2 was used for all infections. Virus was 
removed by centrifugation and replaced with complete growth media approximately 20 
hours after the addition of virus. Cells were allowed a 24 to 48 hour recovery period prior 
to the addition of puromycin (Sigma P9620) at a final concentration of 2 µg/mL to select 
for successfully infected cells. Puromycin selection was performed for a minimum of 72 
hours before any subsequent assays. Non-infected control cells that were subjected to the 
same procedure were included in all cell infections. Quantitative real-time polymerase 
chain reaction (qRT-PCR) for expression of the human Spy1 gene was performed to 
quantify infection efficiency.  
 
IX. HL-60 Cell Proliferation Assays 
Upon successful selection in puromycin, cells expressing pLKO and pLKO-
shSpy1 were counted using Trypan Blue exclusion and cell counts performed using a 
BioRad TC10 Automated Cell Counter. 100,000 cells were seeded in 6 well plates in 
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complete growth media and cell counts were performed in triplicate every 24 hours for 3 
days using Trypan Blue exclusion. Wildtype HL-60 cells were also included. 
 
X. HL-60 Cancer Stem Cell Marker Analysis 
After successful selection in puromycin, cells expressing pLKO and pLKO-
shSpy1 were collected along with wild-type HL-60 cells for qRT-PCR analysis of 
leukemic stem cell markers commonly used as diagnostic markers in acute myelogenous 
leukemias. Genes examined were human CD33 and CLL-1. mRNA levels of each gene in 
cells exhibiting Spy1 knock-down were compared to levels in pLKO-infected control 
cells. 
 
XI. HL-60 Cell Differentiation 
To induce granulocytic differentiation, 1 x 10
5
 cells were seeded in 6 well plates. 
Differentiation medium consisted of complete growth media with the addition of atRA at 
a final concentration of 1 µM. Additional cells were also seeded in media containing 
0.1% ethanol to serve as vehicle controls. Cells were allowed to differentiate over a 
period of 5 days; media was changed every 48 hours and cells were grown in the dark. 
Vehicle control and differentiated cells were collected 3 days and 5 days after the addition 
of atRA for further analysis.  
 
XII. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Total RNA was extracted from cell pellets using an RNeasy Extraction Kit 
(Qiagen 74134). Briefly, samples were lysed and homogenized prior to the removal of 
genomic DNA. Ethanol was used to enhance binding of RNA to an RNeasy spin column 
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and a series of wash steps were performed before elution of RNA using RNase-free 
water. RNA concentrations and quality were assessed on a NanoDrop Spectrophotometer 
(ND-1000 software version 3.3.0 Thermo Scientific). RNA was reverse transcribed using 
Superscript II reverse transcriptase (Invitrogen 100004925), 0.5 µg Oligo dT’s (Eurofin) 
and 0.5 µg random nanomers (Thermo Scientific SO142). qRT-PCR was performed using 
Fast SYBR green detection (Applied Biosystems 4385616) on an ABI Viia7 thermocycler 
(Applied Biosystems 278880504). All qRT-PCR reactions were performed for 55 cycles 
and the stages were as follows: denaturation of cDNA was performed at 95ºC for 1 
minute; annealing of primers to single stranded DNA occurred at 60ºC for 20 minutes; 
elongation occurred at 72ºC for 30 seconds. All gene-specific primers were used at a 
concentration of 5 µM with the exception of murine Spy1 and murine Sca-1 primers 
which were used at a concentration of 6 µM. Primer pairs are listed in Table 1. All data 
were normalized to GAPDH as an internal control.  
 
XIII. qRT-PCR Calculations 
All qRT-PCR reactions were analyzed using Viia7 software version 1.1.5 to 
generate Ct values. Briefly, the Ct of all target genes is balanced to that of the internal 
control, GAPDH, such that ΔCt values are calculated (example: ΔCtSpy1 48hr = CtSpy1 48hr – 
CtGAPDH 48hr). The sample to which all other samples will be compared is then set to zero 
to generate ΔΔCt values; in this case, wildtype cells, pLKO control cells, or 0hr time 
points for differentiation experiments were set to zero (example: ΔΔCtSpy1 48hr = ΔCtSpy1 
48hr – ΔCtSpy1 0hr). The relative quantification (RQ) value is then calculated by taking 2
-ΔΔCt
 
(example: RQSpy1 48hr =  2
-ΔΔCt
Spy1 48hr). All data represents log10 relative quantification. 
Error bars represent the standard error of the mean ΔCt value. 
22
 Table 1. Murine qRT-PCR Primer Pairs 
 
Murine 
Gene 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
GAPDH GATGCCCCCATGTTTGTGAT GTGGTCATGAGCCCTTCCA 
Spy1 GCTTTAGGGAAAAACTGGAGA
AAA 
AATGGCCATGACCTCTTCACA 
c-kit GGGCAAGAGTTCCGCCTTCTT GCTGCGACCACAAAGCC 
Sca-1 CTCTGAGGATGGACACTTCT GGTCTGCAGGAGGACTGAGC 
CD34 GAGAATTCTGGAATCCGAGAA
GTGAGGT 
ACTCTAGAACCCAGCCTTTCTCC
TGTAG 
Mac-1 GCCAATGCAACAGGTGCATAT CACACATCGGTGGCTGGTAG 
Gr-1 TGGACTCTCACAGAAGCAAAG GCAGAGGTCTTCCTTCCAACA 
C/EBPε GACCTACTATGAGTGCGAGCC
T 
ACACCCTTGATGAGGGTAGCAG 
 
 
Table 2. Human qRT-PCR Primer Pairs 
 
Human 
Gene 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
GAPDH GCACCGTCAAGGCTGAGAA
C 
GGATCTCGCTCCTGGAAGATG 
Spy1 TTGTGAGGAGGTTATGGCCA
TT 
GCAGCTGAACTTCATCTCTGTTGT
AG 
CD33 AAGTACAGGAGGAGACTCA
GG 
GTGATTATGAGCACCGAGG 
CLL-1 GTGATGATGTCCAAACATGG
C 
GATTGATGCCTCATGCCTCC 
Mac-1 AGTTGCCGAATTGCATCGA GGCGTTCCCACCAGAGAGA 
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XIV. Statistical Analysis 
All statistical analyses for qRT-PCR data was performed with the use of a 
Student’s paired t-test. Data were only taken as significant if the p-value was less than 
0.05. For statistical analysis on the tissue microarray of human multiple myeloma samples 
(TMA T293) a Student’s paired t-test was performed in Statistica software.  
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RESULTS 
I. Spy1 Protein is Expressed in Mammalian Sites of Hematopoiesis 
To analyse protein expression of Spy1 in tissues known to be implicated in blood 
cell production and maturation, tissue microarray analysis was performed. Tissue samples 
present on the microarray represent those of a human fetus at age 5 months gestation. 
Tissues were stained with anti-Spy1 and anti-rabbit-Alexa 488 antibodies as well as 
TOTO-3 nuclear control stain in order to quantify Spy1 protein levels. Although several 
human tissues were analysed, those of interest to blood cell development are the thymus, 
liver, spleen, and bone.  Results indicate that Spy1 is expressed at the protein level in the 
thymus, liver, spleen, and bone and that this expression is moderate in comparison to 
other tissues represented on the microarray (Figure 3A). Interestingly, of the 
hematopoietic tissues examined, Spy1 was expressed to the greatest extent in the liver and 
the bone.  
Further analysis on liver, spleen, and thymus samples from Balb/C mice at post-
natal age 7 and 21 days was performed using SDS-PAGE and immunoblotting (Figure 
3B). Results were quantified using densitometry and Spy1 protein levels were analyzed 
relative to an internal control protein, actin. Results indicate that Spy1 protein is 
expressed in all the murine hematopoietic tissues sampled thus far. Remaining consistent 
with the tissue microarray data, Spy1 protein was expressed to the highest extent in the 
liver. Furthermore, levels of Spy1 protein showed, at minimum, a 2 fold decrease at each 
site by day 21. Overall, these results show that Spy1 is expressed in mammalian tissues 
important for hematopoietic development. 
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Figure 3. Spy1 protein is expressed in mammalian hematopoietic tissues. (A) Spy1
protein levels in human fetal samples as measured by tissue microarray analysis. Values
are presented as relative to the nuclear control TOTO-3. Error bars represent standard
error of the mean of at least 3 separate samples for each tissue. Hematopoietic tissues are
highlighted in red boxes. (B) Levels of Spy1 protein in Balb/C spleen, liver, and thymus
tissue samples extracted at post-natal days 7 and 21. Densitometry analysis depicts the
ratio of Spy1 protein relative to loading control (β-Actin). Error bars represent standard
error of the mean of 3 protein lysates from each tissue.
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II. Spy1 Expression Decreases During EML Myeloid Differentiation 
The multipotent murine bone marrow cell line, EML, was used as a model for 
hematopoietic myeloid differentiation. EML cells were stimulated to differentiate down 
the myeloid cell lineage to become more committed early progenitor cells capable of 
producing many myeloid cell types (Figure 4A). Specifically, EML cells were given 
murine IL-3 and atRA over a time period of 3 days. Control cells were grown in the 
absence of IL-3 and atRA. mRNA expression of Spy1 relative to EML control cells was 
evaluated every 24 hours using qRT-PCR. Results indicate that both of the stem cell 
markers c-kit and Sca-1 significantly decrease over time (Figure 4B & 4C) while the 
myeloid specific differentiation markers, Mac-1 and Gr-1, both increase over time (Figure 
4D & 4E). Collectively, these results indicate that the EML cells were successfully 
undergoing myeloid differentiation. Furthermore, it was demonstrated that Spy1 mRNA 
consistently decreases as EML cells are forced to differentiate into myeloid progenitor 
cells; at least a 3-fold decrease was observed at all time points (Figure 4F). These results 
were found to be statistically significant. 
 
III. Spy1 Expression is Elevated in CD34+ EML Cells 
It has previously been shown that EML cells are a heterogeneous population of 
multipotent blood cells
30,86
. Immunomagnetic sorting using anti-CD34 antibody was 
performed to isolate the CD34
+
 and CD34
-
 populations of EML cells; these populations 
have been shown previously to possess stem-like characteristics
26,52,86-87
. qRT-PCR 
analysis of CD34 mRNA levels shows successful sorting of CD34
+
 and CD34
-
 cells 
(Figure 5A). qRT-PCR analysis of Spy1 mRNA levels within each population compared 
to a heterogeneous population was also performed (Figure 5B). Although these data 
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Figure 4. Spy1 expression decreases during EML myeloid differentiation. (A) A sche-
matic representation of EML cell differentiation. Differentiation steps (arrows) and
growth factors used are marked in red. (B-F) qRT-PCR was used to analyze mRNA levels
of stem cell markers: c-kit (B) and Sca-1(C) as well as myeloid specific differentiation
markers: Mac-1 (D) and Gr-1(E), and Spy1 (F). All data are normalized to GAPDH and are
expressed as relative quantification (RQ) on a logarithmic scale (log 10). Error bars repre-
sent standard error of the mean of three independent experiments each run in triplicate.
Statistical analysis was performed using a Student’s paired t-test (*p<0.001, **p<0.002,
***p<0.005, ****p<0.05)
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represent only two independent experiments, these preliminary results indicate that Spy1 
is elevated in the CD34
+
 population; this is an approximately 50 fold increase over the 
CD34
-
 EML cell population. Taken together, the results presented in Figures 4 and 5 
demonstrate correlative expression of Spy1 in early stem and MPP cells in the 
hematopoietic system. 
 
IV. Spy1 Expression Increases During EML Terminal Myeloid Differentiation  
EML cells that were successfully differentiated into myeloid progenitor cells were 
further stimulated with murine GM-CSF and atRA to induce differentiation into terminal 
cells of the granulocyte and monocyte lineages (Figure 6A). It is important to note that 
EML-derived myeloid progenitors are absolutely dependent on GM-CSF for growth; 
therefore, control cells were grown in the absence of atRA and the presence of GM-CSF. 
Gene expression of Spy1, c-kit, and the myeloid specific differentiation markers, Mac-1 
and C/EBPε, was analyzed using qRT-PCR every 24 hours for a period of 72 hours. 
Results show that myeloid progenitor cells were successfully differentiating into terminal 
myeloid cells as indicated by the decrease in c-kit expression (Figure 6B) and the increase 
in both Mac-1 (Figure 6C) and C/EBPε (Figure 6D) expression. However, the control 
cells showed a slight increase in Mac-1 and C/EBPε, indicating spontaneous 
differentiation potentially as a result of GM-CSF. Although results were inconsistent with 
regards to Spy1 expression levels between 4 independent experiments, results do suggest 
that Spy1 may be increased at the gene expression level during these later stages of 
differentiation (Figure 6E).  
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Figure 5. Spy1 expression is elevated in CD34 + EML cell populations. Relative
mRNA levels of CD34 (A) or Spy1 (B) were assessed by qRT-PCR in heterogenous EML
populations, CD34 enriched populations (CD34+), and the CD34 negative populations
(CD34-). Data arenormalizedto GAPDH and arepresented as the relative quantification
(RQ) depicted on a logarithmic scale (log10). Error bars represent the standard error of the
mean of two independent sorts each run in triplicate qRT-PCR reactions.
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Figure 6. Spy1 mRNA levels increase during EML terminal myeloid differentiation.
(A) Schematic representation of EML cell line differentiation. The differentiation steps
performed in this experiment are shown in red. (B-E) qRT-PCR analysis of the mRNA
levels of: the stem cell marker c-kit (B), the differentiation markers Mac-1 and C/EBPε (C
& D respectively) , and Spy1 (E). All data are normalized to GAPDH endogenous control
and data are presented as relative quantification (RQ) on a logarithmic scale (log 10). Error
bars represent standard error of the mean of four independent experiments each run in
triplicate. Statistical analysis was assessed by the Student’s paired t-test (*p<0.001,
**p<0.05).
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V.  Leukemia Cell Growth Decreases in the Absence of Spy1 
To study the role of Spy1 in leukemic stem cell populations, a human acute 
promyelocytic cell line was chosen as a representative case of AML. HL-60 cells were 
infected with lenti-virus to express pLKO-shSpy1 or with pLKO-shScrambled (pLKO) as 
a control. qRT-PCR analysis was used to confirm the knock-down of Spy1; results 
demonstrate approximately an 8 fold decrease in the expression of Spy1 in cells infected 
with pLKO-shSpy1 compared to control pLKO cells (Figure 7A). Cells successfully 
expressing pLKO and pLKO-shSpy1 were selected by growth media containing 
puromycin. After 72 hours of selection, 100% of wildtype HL-60 cells were dead, while 
100% of pLKO and approximately 80% of pLKO-shSpy1 cells were alive, indicating 
they were successfully infected (Figure 7B-G). To assess the effect Spy1 depletion would 
have on HL-60 cell growth, 100,000 cells were seeded in 6 well plates for each construct 
and cell number was assessed every 24 hours using Trypan Blue Exclusion and cell 
counts performed in triplicate. Results indicate that HL-60 cells exhibiting Spy1 knock-
down grow more slowly than both pLKO control and wildtype cells at all time points 
(Figure 8). After 72 hours of growth pLKO-shSpy1 cells have multiplied to produce 
approximately 3.5 x 10
5 
cells, whereas pLKO control cells have nearly double the cell 
number (6 x 10
5
 cells). Therefore, it is evident that HL-60 cells grow significantly slower 
when Spy1 is depleted. These results were found to be statistically significant. 
 
VI. Expression of LSC Genes Decreases in the Absence of Spy1 
CLL-1 and CD33 are both known to be highly expressed on leukemia cells in 
patients with AML, but not on normal HSCs or non-myeloid cells
66,68,70,88
. In addition, 
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Figure 7. Successful shRNA-mediated knock-down of Spy1 in HL-60 cells. HL-60
cells were infected with lentivirus carrying shRNA against Spy1 (pLKO-shSpy1) or a
scrambled control (pLKO). (A) qRT-PCR was used to assess knock-down efficiency. Data
is normalized to GAPDH andpresented as relative quantification (RQ) on a logarithmic
scale (log10). (B-G) Microscopy images of cells treated with Puromycin. (B, D, and F)
Total magnification of 100x.(C, E, and G) Total magnification of 200x.
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Figure 8. Spy1 knock-down slows HL-60 cell growth. Trypan blue exclusion assay was
performed to assess cell proliferation of HL-60 cells successfully infected with shRNA
against Spy1(pLKO-shSpy1) or scrambled control (pLKO). over a period of 72 hours.
Error bars represent the standard error of the mean viable cell number of three indepen-
dent experiments each counted in triplicate. Statistical analysis using a Student’s paired t-
test was performed to compare growth of pLKO to pLKO-shSpy1 cells (#p<0.001) and to
wildtype cells (*p<0.001, **p<0.005) at all time points.
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CLL-1 and CD33 have been previously studied as potential LSC targets in clinical trials 
for treatment of human AML
66-67,69
. Following selection in puromycin, cells exhibiting 
successful knock-down of Spy1 were analysed by qRT-PCR for expression of both CLL-
1 and CD33. Results indicate that both CLL-1 and CD33 levels are decreased in HL-60 
cells expressing shSpy1 when compared to control pLKO cells (Figure 9). More 
specifically, an approximate 3 fold decrease in the expression levels of CLL-1 and an 
approximate 4 fold decrease in the expression levels of CD33 were observed. These 
results indicate a potential role for Spy1 in promoting formation of LSC populations in 
AML. 
 
VII. Spy1 Expression Increases During HL-60 Differentiation 
To examine whether Spy1 levels may be altered by current therapeutic regimens 
for AML, HL-60 cells were treated with atRA. Specifically, HL-60 cells were cultured in 
media containing atRA for 5 days to allow for granulocytic differentiation or in media 
containing 0.1% ethanol as a vehicle control. Cells were analysed using qRT-PCR for 
expression of the human myeloid cell marker Mac-1 and for Spy1 at 3 days and 5 days 
after the addition of atRA (Figure 10). Preliminary results demonstrate that Mac-1 
expression levels increase as HL-60 cells differentiate, demonstrating an approximate 5.6 
fold increase in expression over vehicle control cells by 5 days differentiation. Spy1 gene 
expression also increased as HL-60 cells differentiated, demonstrating approximate 5 fold 
and 16 fold increases in expression over cells treated with a vehicle control at 3 and 5 
days atRA differentiation, respectively. Interestingly, this result is consistent with the 
increase of Spy1 observed during atRA-induced terminal differentiation of EML cells.  
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Figure 9. Expression of LSC gene decreases in the absence of Spy1. Cells successfully
infected with either pLKO-shScrambled (pLKO) or pLKO-shSpy1 constructs were col-
lected and analyzed for expression of known leukemic stem cell markers for acute
myelogenous leukemia. qRT-PCR was used to analyze mRNAlevels of CLL-1 and CD33.
Data was normalized to GAPDH and shown as relative quantification (RQ) on a logarith-
mic scale (log10). Error bars represent standard error of the mean of two independent
experiments.
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Figure 10. Spy1 expression increases during HL-60 cell differentiation. HL-60 cells
were stimulated to differentiate into terminal granulocytes using atRA. Cells treated with
a vehicle control (EtOH) are also shown. qRT-PCR analysis of Spy1 and of the differenti-
ation marker Mac-1 show mRNA levels at 3 and 5 days differentiation. Data is normal-
ized to GAPDH as an internal control and all data is represented as relative quantification
(RQ) on a logarithmic scale (log10). Error bars represent the standard error of the mean of
three replicates of the same sample.
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VIII. Spy1 Protein is Significantly Elevated in Myelomas 
To examine levels of Spy1 in a more differentiated blood malignancy, tissue 
microarray analysis of human bone marrow-derived myeloma tumours was performed. 
Specifically, Spy1 protein levels were examined in a variety of human myeloma samples 
relative to levels in normal bone marrow. Paraffin-embedded tissues were stained with 
anti-Spy1 antibody followed by Alexa488 fluorescent conjugated secondary antibody and 
a nuclear control, TOTO-3. Results indicate that Spy1 protein is expressed in normal 
human bone marrow and that this expression is significantly elevated in all of the tumour 
samples examined to date (Figure 11). For example, Spy1 protein was expressed at levels 
more than ten times as great as those observed in normal marrow (Figure 11; Myeloma of 
the Vertebrae). Spy1 protein was increased to the least extent in Ewing’s sarcoma, but 
even this expression was three times that of normal marrow samples (Figure 11). 
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Figure 11. Spy1 protein is significantly elevated in multiple myelomas. Levels of Spy1
protein relative to a nuclear control stain, TOTO-3 are graphed. Tissues are representative
of four different types of multiple myeloma (n=16) (myeloma of the vertebrae, plasma
cell myeloma of the pubis, Ewing’s sarcoma, and myeloma of the neck) and normal bone
marrow tissue (n=8). Samples were obtained from human patients ranging in age from
10-57 years. Error bars represent the standard error of the mean. Statistical significance
was assessed using a student’s paired t-test in Statistica software (*p=0.001, **p=0.0003,
***p=0.00001)
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DISCUSSION 
 Collectively blood malignancies are the 4
th
 most common cancer diagnosed in 
both men and women worldwide
1
. Despite overall drops in mortality due to advances in 
treatment and earlier diagnosis, leukemias still have a poor prognosis with an overall five 
year survival rate of only 51%
1
. Blood malignancies represent a diverse group of cancers 
with many genetic backgrounds, not all of which have been resolved to date. The findings 
presented in this study have demonstrated involvement of the novel cell cycle regulator, 
Spy1, in normal hematopoietic cell development and suggest implications for Spy1 in the 
development of LSCs. 
 To determine whether Spy1 protein was expressed in tissues known to play 
important roles in the hematopoietic system, tissue microarray analysis was performed. It 
was found that Spy1 was expressed, at the protein level, rather ubiquitously across many 
human fetal tissues. Notably, Spy1 protein was found to be expressed in fetal tissues 
known to support hematopoietic cell development including the spleen, thymus, and liver. 
This is consistent with previous work which demonstrated Spy1 expression in many 
human tissues including the liver and thymus
76
. Of the tissues examined in this study, 
Spy1 protein levels were greatest in the liver. The liver plays a very prominent role in 
development of the hematopoietic system by supporting hematopoiesis for a large portion 
of fetal development
37,39,41
. It is notable that Spy1 has been found to be involved in 
hepatocellular carcinoma
89
; hence, whether expression is occurring in the hematopoietic 
cells or early hepatic cells from these data is not known. 
 These results were further supported by western blot analysis of murine spleen, 
thymus, and liver tissues where Spy1 protein was found to be expressed at 7 and 21 days 
post-natal development. Consistent with the tissue microarray analysis, Spy1 was 
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expressed to the greatest extent in the liver. The murine liver has been shown to support 
HSC production and development for a short period of time post-natally
39 
and HSCs have 
recently been identified in the adult mammalian liver
41,90
. Moreover, the presence of 
hematopoietic progenitors capable of forming hematopoietic colonies in vitro has been 
observed in many murine adult organs including the liver and the spleen
90-91
. Therefore, 
this result provides further evidence that Spy1 is expressed in tissues important in early 
hematopoietic development. Furthermore, densitometry analysis shows that Spy1 protein 
expression decreased by day 21 in all tissues examined. The proportion of HSCs in 
hematopoietic tissues is known to be the greatest in younger mammals due to a 
developmental need
34
; thus, the decrease in Spy1 protein levels observed in older murine 
samples may be explained by a decrease in the proportion of early stem and progenitor 
cells in these tissues. However, due to the many cell types present in each of these tissues, 
future steps should involve cell sorting in order to draw any direct conclusions between 
Spy1 and HSC development in these tissues. 
 To further clarify a role for Spy1 in hematopoietic cell development, murine bone 
marrow cells capable of erythroid, myeloid, and lymphoid (EML) differentiation in 
response to different growth factors in vitro were utilized
30,86
. EML cells are 
representative of the MPP population in hematopoietic development expressing the cell 
surface markers c-kit, Sca-1, and some early lineage progenitor markers
30
. EML cells 
have previously been immortalized by the expression of a dominant negative retinoic acid 
receptor; this induces a block in EML myeloid differentiation that can be overcome with 
very high concentrations of all-trans retinoic acid
30
. For the purposes of this study, EML 
cells were induced to differentiate down the myeloid pathway by the addition of IL-3 and 
atRA to generate the more committed myeloid progenitor cells, termed GMPs. Results 
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show a significant decrease in Spy1 gene expression during the initial stages of EML 
myeloid differentiation, demonstrating that Spy1 levels correlate with stages of 
development focused on maintaining the early hematopoietic stem and progenitor cell 
populations. This is consistent with previous work in our lab showing that Spy1 levels 
correlate with its ability to regulate stemness decisions in both the breast and the 
brain
84,92
. Future experiments in which Spy1 levels are manipulated prior to 
differentiation will be necessary to further substantiate the functional importance of this 
expression pattern and provide direct evidence that Spy1 plays a role in directing HSC or 
MPP fate. 
 As previously mentioned, EML cells are known to be a heterogeneous population 
of MPP cells expressing early stem cell genes such as c-kit and Sca-1, but also expressing 
markers for early lineage progenitor cells
30
. Furthermore, EML cells contain both a 
CD34
+ 
and CD34
-
 population of cells with different capacities to proliferate and 
differentiate
86
. To determine if Spy1 is differentially expressed in certain populations of 
the HSC compartment, EML cells were subject to immunomagnetic sorting to isolate 
CD34
+ 
and CD34
-
 populations. Results demonstrate an approximate 50 fold increase in 
Spy1 gene expression levels in the CD34
+
 EML population in comparison to both the 
CD34
- 
and the heterogeneous EML populations. This finding further demonstrates that 
Spy1 expression correlates with the stages of hematopoietic development involving the 
early CD34
+
 stem and MPP cells. Differential expression of CD34 in the murine 
hematopoietic stem cell compartment mirrors the proliferative status of the cell 
populations. Relatively quiescent LT-HSCs residing in the bone marrow niche are CD34
-
 
and capable of long-term engraftment
25-26,28,93
. In contrast, ST-HSCs and MPPs have 
transient engraftment ability, can be mobilized from the marrow, and are CD34
+ 25-26,28,93
. 
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Despite these established correlative patterns, it is notable that differences in cell surface 
protein expression have not been definitively linked as playing a causative role in the 
functional differences between ST-HSCs and MPPs
25-26,52,87,94
. Spy1 is expressed to a 
greater extent in the ST-HSCs and MPP cells and, therefore, Spy1 may be important in 
fate decisions of these cells, however, this functional role needs to be directly assessed. 
EML-derived GMP cells are dependent on GM-CSF for survival and can 
spontaneously produce mature monocytes and macrophages. However, EML-derived 
GMP cells display a defect in terminal granulocyte differentiation that can be overcome 
with high concentrations of atRA
30
. To determine how Spy1 levels correlate with these 
later stages of development, EML-derived GMP cells were induced to terminal 
differentiation with GM-CSF and atRA. Control cells were grown in GM-CSF containing 
medium. Interestingly, Spy1 mRNA levels were found to be elevated during the terminal 
differentiation of EML cells, although changes in Spy1 levels were not significantly 
greater than those observed in control cells. This may be due to the fact that EML-derived 
GMPs are capable of spontaneously differentiating down the monocytic pathway; 
therefore, differentiated cells of the monocyte lineage are likely present in the control cell 
populations as indicated by the increases in Mac-1 and C/EBPε in these cells.  
Although LT-HSCs and ST-HSCs have the highest capacity for self-renewal of all 
hematopoietic cells, it has been discovered that MPPs, early and late lineage progenitor 
cells, and even some mature blood cells maintain a proliferative index due to the high 
turnover of blood cells
95-96
. Spy1 has been shown to be necessary for proliferation in a 
variety of mammalian cell types
76,82,84,92
; therefore,  perhaps Spy1 is elevated during the 
differentiation of GMP cells to aid in proliferation of lineage progenitors and mature 
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blood cells lower in the hierarchy. Alternatively, since Spy1 levels were only analysed at 
the mRNA level, it is possible that Spy1 protein continues to decrease during GMP 
differentiation, but that this is regulated at the translational or post-translational level. 
Overall, this result may suggest broader implications for Spy1 in hematopoietic 
development as it indicates a potential need for Spy1 in later stages of blood cell 
differentiation. 
 Collectively, these in vitro experiments indicate that Spy1 expression correlates 
with proliferative stages of myeloid development including the early stem and MPP 
stages; therefore, subsequent experiments aimed to elucidate a role for Spy1 in AMLs 
known to have LSC populations. HL-60 cells are human leukocytes consisting primarily 
of neutrophilic promyelocytes taken from a patient with acute promyelocytic leukemia
94
. 
HL-60 cells were subjected to shRNA-mediated knock-down of Spy1 and effects on 
growth were assessed using trypan blue exclusion and cell counts. It was observed that 
HL-60 cells grew more slowly in the absence of Spy1 in comparison to both control 
pLKO cells and wildtype HL-60 cells. This demonstrates that Spy1 plays an important 
role in promoting cell growth and proliferation in this representative case of AML. These 
results are consistent with previous data demonstrating a proliferative role for Spy1 in 
mammalian cells
76,82,84,97
. Further exploration of these effects in a wide panel of AML cell 
lines is needed. 
 Furthermore, HL-60 cells have been found to express high levels of the LSC 
specific markers CLL-1
69
 and CD33
66
. CLL-1 and CD33 have been extensively studied 
and identified as potential LSC targets important in drug development and clinical trials 
for the treatment of human AML
66-67,69
. Interestingly, when Spy1 was depleted using 
shRNA in HL-60 cells, gene expression levels of both CLL-1 and CD33 decreased as 
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assessed by qRT-PCR. This finding indicates a role for Spy1 in promoting the expression 
of known LSC markers. Taken together, these results suggest a role for Spy1 in 
promoting formation of LSC populations in this representative case of AML. This is 
consistent with previous work from our lab and others demonstrating the involvement of 
Spy1 in aggressive forms of breast and brain cancer and that Spy1 can promote the 
expression of CSC markers important in driving tumour formation
84,92,99-100
. Future 
experiments utilizing sorted CLL-1
+
 and CD33
+
 HL-60 cell populations are necessary to 
accurately examine the effects of Spy1 knock-down on growth and proliferation of the 
LSC compartment of HL-60 cells. 
 To address whether Spy1 levels are altered during therapeutic treatment of AML, 
HL-60 cells were differentiated with atRA to mimic current treatment of acute 
promyelocytic leukemia in the clinic. Promyelocytic leukemia is characterized by an 
accumulation of promyelocytes in the bone marrow that are unable to complete 
granulocytic differentiation
8
; treatment with atRA has seen much success clinically
5-8
, 
however, cases of atRA resistant myelocytic leukemia have been reported
101
. As 
previously observed, knock-down of Spy1 has effects on both leukemic cell growth and 
LSC marker expression in this cell line. Therefore, it was my hypothesis that knock-down 
of Spy1 might sensitize HL-60 cells to differentiation treatment with atRA. Surprisingly, 
initial experiments examining endogenous levels of Spy1 during HL-60 atRA 
differentiation showed an increase in Spy1 gene expression as cells became mature 
granulocytes. Although this result is not consistent with the hypothesis for this 
experiment, it is similar to the observations made during atRA induced terminal EML 
maturation and may be explained by the proliferative potential maintained by late lineage 
progenitors and mature blood cells
95-96
. Furthermore, it is important to note that Spy1 
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levels were only examined at the mRNA level; protein analysis should be completed 
before drawing final conclusions as it is possible that Spy1 is being regulated differently 
at the translational level. Furthermore, functional effects of the knockdown of Spy1 on 
success of treatment will require assays measuring overall cell growth properties 
following treatment, including clonal assays to measure the effects on the LSC 
population.   
 Lastly, tissue microarray analysis was performed to analyse protein expression of 
Spy1 in human blood malignancies. Due to the endogenous expression of Spy1 observed 
in late stage hematopoietic cells, a more differentiated blood malignancy, multiple 
myeloma, was analyzed for expression of Spy1. Multiple myeloma is a plasma cell 
malignancy affecting B lymphocyte development within the hematopoietic system
49
. 
Results demonstrate that Spy1 protein is expressed in normal bone marrow, but that this 
expression is significantly elevated in all of the myeloma tumours examined. This finding 
implies that Spy1 may be important in myeloma and warrants further investigation into a 
role for Spy1 in myelomas. Interestingly, this result suggests a link to Spy1 in a more 
differentiated cancer in contrast to previous work from our lab showing implications for 
Spy1 in aggressive breast and brain cancers of a stem cell origin
84,92
. This may be 
explained by the fact that mature blood cells of the B cell lineage are highly proliferative 
and can undergo clonal expansion during immune reactions
34,96
. Future directions may 
aim to examine a role for Spy1 in EML B Cell differentiation decisions.  
 In summary, this study has demonstrated that Spy1 is expressed in mammalian 
sites important to both murine and human hematopoiesis. Taken together, the decrease in 
Spy1 expression during in vitro differentiation of EMLs and the high expression of Spy1 
in CD34
+
 EML populations demonstrate that Spy1 is endogenously expressed within the 
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ST-HSC and MPP compartment of the hematopoietic hierarchy. However, findings also 
indentified Spy1 to be expressed in more mature hematopoietic cells. Collectively, these 
in vitro experiments demonstrate a correlation between Spy1 expression and proliferative 
stages of the hematopoietic hierarchy. Furthermore, these findings identify Spy1 as 
important in promoting development of LSCs in one subtype of AML and it was revealed 
that Spy1 is significantly elevated in a variety of human myelomas. Overall, this study 
demonstrates that Spy1 may have broader implications in blood malignancies than the 
previously identified role in some types of lymphoma
85
. These findings may have 
implications into the future treatment of different blood malignancies. 
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Appendix A 
Gene Manipulation in EML Cells 
This appendix reviews in detail the many different techniques attempted for both 
transfection of plasmid DNA and infection using lenti-virus. In all cases, successful 
transfection was assessed using a GFP reporter and light microscopy. 
 
I Transfections 
Transfections with polyethylenimine (PEI) 
EML cells were seeded in 12 well plates at densities of 0.5 x 10
5
 cells/mL, 1.0 x 10
5
 
cells/mL, and 2.0 x 10
5
 cells/mL in serum-free media on the day of transfection. Plasmid 
DNA for both the pEIZ control and pEIZ-Spy1 were diluted at a ratio of 1:10 in 150mM 
NaCl. 1 µg plasmid DNA was then mixed with 5 µL of 10 mg/mL polyethylenimine 
(PEI) in eppendorf tubes. This mixture was allowed to incubate at room temperature for 
10 minutes prior to addition to cells. The plate was centrifuged for 5 minutes at 500 x g 
and 4ºC. Following this centrifugation, media was replaced with serum-free media either 
immediately or after approximately 16 hours. 
 
Transfections with JetPrime Reagent 
EML cells grown to approximately 75% confluency in 5 mL of complete growth media in 
6 cm plates were transfected with GFP plasmid DNA using Jet Prime Reagent (VWR 
CA89129-922) and following the manufacturer’s protocol. Briefly, plasmid DNA was 
added to Jet Prime buffer in an eppendorf tube and vortexed prior to the addition of Jet 
Prime Reagent. Following an incubation period of 10 minutes at room temperature, 
plasmid DNA, Jet Prime Reagent, and buffer mixture was added to cells. Different ratios 
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of plasmid DNA to Jet Prime Reagent and buffer can be found in table 3. Each 
transfection was performed in duplicate so that transfection times of both 4 hours and 20 
hours could be attempted.  
 
Table 3. EML Transfection with JetPrime, Conditions 
 GFP Plasmid 
DNA  (µg) 
Amount JetPrime 
Reagent (µL) 
Amount Buffer 
(µL) 
Transfection 1 1.0 2 100 
Transfection 2 2.0 3 200 
Transfection 3 4.0 4 200 
 
 
II Infections with Lenti-Virus 
Lenti-viral Infection 
5,000, 10,000, 25,000 or 50,000 EML cells were seeded in 96 well plates in serum-free 
and antibiotic-free media on the day of infection. Polybrene was added to media at final 
concentrations ranging from 1 µg/mL to 8 µg/mL. In some instances lenti-virus 
containing either the pEIZ control vector, pEIZ-Spy1, pLB-shScrambled, and pLB-
shSpy1were added immediately after the addition of polybrene. In other instances, cells 
were allowed to incubate in media-containing polybrene for 20 to 30 minutes prior to the 
addition of virus. Viral titres for all constructs were 10
7
 TU/mL and different MOIs 
ranging from 0.1 to 10 were attempted. EML cells were allowed to incubate with virus for 
a minimum of 6 hours to a maximum of 24 hours. Upon removal of virus-containing 
media, complete growth media was added. 
 
Lenti-viral Infection – Spinoculation 
50,000 EML cells were seeded in 96 well plates in serum-free media containing 4 to 8 
µg/mL polybrene. After the addition of lenti-virus containing pEIZ control and pEIZ-
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Spy1, plates were subject to centrifugation at either 1500 rpm or 800 x g for 10 to 30 
minutes at 32ºC. Following centrifugation, media was then replaced with complete 
growth media. Alternatively, plates were allowed to incubate for a minimum of 6 hours 
and a maximum of 24 hours before the removal of virus. MOI ranged from 1 to 5. 
 
Lenti-viral Infection with Magnetic Beads 
50,000 EML cells were seeded in 96 well plates in serum-free media containing 4 µg/mL 
polybrene for infection with pEIZ control and pEIZ-Spy1. A mixture of magnetic beads 
and virus was prepared at a ratio of 1 µL to 10 µL, respectively, and allowed to incubate 
on ice for 30 minutes. During this incubation, bead-virus mixtures were vortexed every 5 
minutes. Prior to the addition of the bead-virus mixture, plates were centrifuged for 5 
minutes at 1500 rpm. Plates were then placed on a magnet and allowed to incubate for 20 
minutes in a 37ºC humidified incubator. Virus-containing media was replaced with 
complete growth media approximately 16 hours later. 
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